

# Sith Sathornsumetee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7827149/publications.pdf>

Version: 2024-02-01

60  
papers

9,119  
citations

136740

32  
h-index

149479

56  
g-index

60  
all docs

60  
docs citations

60  
times ranked

9460  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2007, 25, 4722-4729.	0.8	1,285
2	Stem Cell-like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor. <i>Cancer Research</i> , 2006, 66, 7843-7848.	0.4	1,239
3	Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells. <i>Cancer Cell</i> , 2009, 15, 501-513.	7.7	1,196
4	Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2007, 13, 1253-1259.	3.2	1,005
5	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
6	Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth. <i>Cancer Research</i> , 2008, 68, 6043-6048.	0.4	376
7	Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2005, 23, 9359-9368.	0.8	313
8	Molecularly targeted therapy for malignant glioma. <i>Cancer</i> , 2007, 110, 13-24.	2.0	292
9	Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan. <i>Journal of Clinical Oncology</i> , 2008, 26, 271-278.	0.8	259
10	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2010, 12, 1300-1310.	0.6	207
11	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. <i>British Journal of Cancer</i> , 2009, 101, 1986-1994.	2.9	194
12	Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2006, 12, 860-868.	3.2	187
13	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. <i>Clinical Cancer Research</i> , 2008, 14, 7068-7073.	3.2	166
14	SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 737-45.	1.9	150
15	New treatment strategies for malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1087-1104.	1.1	117
16	ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 8145-8157.	3.2	94
17	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 83, 53-60.	1.4	92
18	Designer Therapies for Glioblastoma Multiforme. <i>Annals of the New York Academy of Sciences</i> , 2008, 1142, 108-132.	1.8	91

#	ARTICLE	IF	CITATIONS
19	Diagnosis and Treatment of High-Grade Astrocytoma. <i>Neurologic Clinics</i> , 2007, 25, 1111-1139.	0.8	86
20	Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. <i>British Journal of Cancer</i> , 2012, 107, 1481-1487.	2.9	83
21	Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. <i>Cancer</i> , 2005, 104, 1478-1486.	2.0	76
22	Twisted tango: brain tumor neurovascular interactions. <i>Nature Neuroscience</i> , 2011, 14, 1375-1381.	7.1	70
23	Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2011, 105, 621-627.	1.4	62
24	Quantitative Ultrastructural Analysis of a Single Spinal Cord Demyelinated Lesion Predicts Total Lesion Load, Axonal Loss, and Neurological Dysfunction in a Murine Model of Multiple Sclerosis. <i>American Journal of Pathology</i> , 2000, 157, 1365-1376.	1.9	59
25	AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 8722-8730.	0.4	54
26	Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 161, 497-507.	2.5	47
27	New approaches to primary brain tumor treatment. <i>Anti-Cancer Drugs</i> , 2006, 17, 1003-1016.	0.7	45
28	Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. <i>Neuro-Oncology</i> , 2008, 10, 330-340.	0.6	41
29	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012, 108, 499-506.	1.4	41
30	Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge. <i>Current Pharmaceutical Design</i> , 2007, 13, 3545-3558.	0.9	40
31	Targeting multiple kinases in glioblastoma multiforme. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 277-292.	1.9	39
32	Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 196, 111270.	2.5	37
33	Parry-Romberg syndrome with fatal brain stem involvement. <i>Journal of Pediatrics</i> , 2005, 146, 429-431.	0.9	29
34	Vandetanib (ZD6474), a novel multitargeted kinase inhibitor, in cancer therapy. <i>Drugs of Today</i> , 2006, 42, 657.	0.7	28
35	Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. <i>Cancer</i> , 2012, 118, 4759-4767.	2.0	26
36	Malignant glioma drug discovery – targeting protein kinases. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 1-17.	2.5	25

#	ARTICLE	IF	CITATIONS
37	Treatment and management of malignant gliomas. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 75-77.	12.5	24
38	Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. <i>Journal of Neuro-Oncology</i> , 2012, 107, 213-221.	1.4	24
39	Assessment of hindlimb gait as a powerful indicator of axonal loss in a murine model of progressive CNS demyelination. <i>Brain Research</i> , 2000, 877, 396-400.	1.1	19
40	ALS Untangled No. 20: The Deanna Protocol. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 319-323.	1.1	19
41	Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281.	3.9	18
42	Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme1. <i>Neuro-Oncology</i> , 2007, 9, 70-74.	0.6	14
43	Targeting Netrin-1 in glioblastoma stem-like cells inhibits growth, invasion, and angiogenesis. <i>Tumor Biology</i> , 2016, 37, 14949-14960.	0.8	12
44	Effect of spinal tap test on the performance of sit-to-stand, walking, and turning in patients with idiopathic normal pressure hydrocephalus. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 53-60.	0.6	10
45	Therapeutic Strategies to Target Multiple Kinases in Glioblastoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 700-711.	0.9	9
46	Molecularly targeted therapy in neuro-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 255-278.	1.0	9
47	Nanostructured lipid base carrier for specific delivery of garlic oil through blood brain barrier against aggressiveness of glioma. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102651.	1.4	7
48	Friday night palsy: an unusual case of brachial plexus neuropathy. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 191-192.	0.6	6
49	Simplified approach for pathological diagnosis of diffuse gliomas in adult patients. <i>Pathology Research and Practice</i> , 2021, 223, 153483.	1.0	6
50	Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2013, 96, 1365-73.	0.4	4
51	Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab093.	0.4	3
52	High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma. <i>World Neurosurgery</i> , 2016, 91, 518-523.e1.	0.7	2
53	Brainstem dysfunction heralding disseminated cryptococcosis. <i>Clinical Neurology and Neurosurgery</i> , 2018, 167, 62-64.	0.6	2
54	Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112979.	2.5	2

#	ARTICLE	IF	CITATIONS
55	ALSUntangled No. 37: Inosine*. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 309-312.	1.1	1
56	An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).. Journal of Clinical Oncology, 2020, 38, 3520-3520.	0.8	1
57	Signal transduction pathways as novel therapeutic targets in malignant glioma. Future Neurology, 2006, 1, 819-829.	0.9	0
58	Teaching Neuro <i>Images</i> : Erdheim-Chester disease (xanthogranulomatous histiocytosis). Neurology, 2015, 85, e79-80.	1.5	0
59	P40: Gait alteration in patients with Idiopathic Normal Pressure Hydrocephalus after cerebral spinal fluid removal. Gait and Posture, 2017, 57, 256-257.	0.6	0
60	High-Grade Astrocytomas. , 2011, , 195-232.		0